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Hepatocellular carcinoma (HCC), as the most common type of primary liver tumor, is the 
third leading causes of cancer mortality worldwide. Usually occurring along with liver 
fibrosis or cirrhosis together with atypical vascularisation pattern, HCC is often hard to 
diagnose. The pathological examination of cytohistological samples is a crucial step in 
the diagnosis of liver cancer that can be a difficult task even for an experienced 
pathologist. Currently classical and immunohistochemical staining techniques as well as 
gene expression profiles are common in clinical practice for the investigation of biopsies 
with suspected HCC. Nevertheless, morphological features have not been proven to be 
clinically significant. Therefore, novel optical diagnostic tools are currently explored that 
are able to detect various biomarkers in cytological and histological samples. In recent 
years, a wide range of optical and spectroscopic techniques, e.g. Raman Spectroscopy 
and Matrix-Assisted Laser Desorption/Ionization imaging mass spectrometry (MALDI 
IMS) have been applied and proven to be reliable methods for cancer diagnostics. 
The objective of the present thesis was to investigate the applicability of Raman 
spectroscopic imaging and MALDI IMS as diagnostic tools for liver cancer detection on 
the cellular and tissue levels. In the first study cells from different liver cancer cell lines 
(HepG2 and SK-Hep1) were analyzed by mean of Raman imaging in order to develop 
new algorithms for prediction of unknown cells from different origin. A support vector 
machine based classification model resulted in a prediction accuracy of 93 % for 
prediction of HepG2 and SK-Hep1 cells. By applying hierarchical cluster analysis to 
Raman maps of each single cell, different cellular compartments such as nucleus, lipid 
droplets and cytoplasm were differentiated and analyzed separately. Using only spectral 
information of cytoplasmic lipids, the prediction accuracy of support vector machine 
classification model improved to 96 % in comparison to 91 % for nuclei, 87 % for 
cytoplasm and 93 % for the complete cell information. Furthermore, the metabolic 
changes during different proliferation stages of HCC cells based on Raman spectra 
were investigated. The data showed high expression of unsaturated fatty acids during 
the proliferation in comparison with apoptosis. Differences in the Raman spectra allowed 
us to classify and predict the proliferation behavior of the cells with an accuracy of 99 %. 
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To investigate the diagnostic capacities of Raman spectroscopy on tissue level, 
predefined malignant and non-malignant regions from patient samples with HCC were 
analyzed. We were able to detect lipids, proteins, collagen and cholesterol ester as 
separate components within the Raman maps and analyzed their distribution in different 
hepatic lesions. A random forest classification model allowed us to predict HCC tissue 
regions with sensitivity of 76 % and specificity of 93 %. The main Raman bands 
important for the model were identified as fatty acid bands and especially attributed to 
palmitic acid, known to play an important role in the HCC development. Furthermore, the 
developed classifier was used in order to predict tumor margins between HCC tissue 
and surrounding fibrosis. Consequently, Raman spectroscopy showed a high potential 
for surgical margin status detection, especially tumor margins. 
As a second diagnostic technique for analyses of localization of different proteins within 
malignant and non-malignant tissue regions MALDI IMS was applied. Four proteins 
(6274, 6647, 6222 and 6853 m/z) with significantly higher expression profile in the HCC 
tissue regions in comparison with non-tumorous liver tissue were identified. The 
developed classification model, based on three most significant proteins, allowed 
prediction of HCC with sensitivity and specificity of 90 %. 
In conclusion, the obtained results showed that Raman and MALDI IMS imaging 
techniques can successfully detect and localize a variety of molecules within a sample. 
We proved that Raman spectroscopy can effectively classify and predict molecular 
changes in liver carcinogenesis on cellular and tissue levels in label-free manner. 
Furthermore, an application of MALDI IMS provides a specific proteomic signature that 





Die häufigste Ursache eines primären Lebertumors ist das Hepatozelluläre Karzinom 
(HCC) und dies ist damit weltweit die dritthäufigste Krebstodesursache. In der Regel 
geht das Karzinom gleichzeitig mit einer Leber-Fibrose oder –Zirrhose und mit 
untypischen Vaskularisationen einher, wodurch sich ein HCC häufig schwer 
diagnostizieren lässt. Die pathologische Untersuchung der zytohistologischen Probe ist 
der entscheidende Schritt für die Diagnose von Leberkrebs. Dies kann selbst für einen 
erfahrenen Pathologen eine schwierige Aufgabe darstellen. In der klinischen Praxis 
werden gegenwärtig klassische und immunhistochemische Färbemethoden sowie 
Genexpressionsprofile zur Untersuchung von Biopsien mit Verdacht auf HCC 
eingesetzt. Dennoch wurden morphologische Besonderheiten nicht auf ihre klinische 
Signifikanz geprüft. Daher werden gegenwärtig neuartige optische Diagnosegeräte 
erforscht, welche in der Lage sein sollen, verschiedene Biomarker in zytologischen und 
histologischen Proben zu detektieren. In den letzten Jahren wurde eine Vielzahl an 
optischen und spektroskopischen Techniken zur Krebsdiagnostik eingesetzt und auf 
deren Methodenzuverlässigkeit getestet, z. B. Raman-Spektroskopie und Matrix-
unterstützte Laser-Desorption/Ionisation Massenspektrometrie (MALDI IMS). 
Ziel der vorliegenden Dissertation, war die Erforschung von Raman-Spektroskopie und 
MALDI IMS als geeignetes Diagnose-Instrument zur Detektion von Leberkrebs auf 
zellulärer- und Gewebe-Ebene. In der ersten Untersuchung, wurden Zellen 
unterschiedlicher Leberkrebs-Zelllinien (HepG2 und SK-Hep1) mittels bildgebender 
Raman-Spektroskopie analysiert, um neue Algorithmen zur Voraussage unbekannter 
Zellen aus abweichenden Quellen zu entwickeln. Ein Support Vector Machine 
basierendes Klassifikationsmodell ergab eine 93 %ige Vorhersagegenauigkeit für die 
Unterscheidung von HepG2 und SK-Hep1. Unter Verwendung einer hierarchischen 
Clusteranalyse auf die einzelnen Raman-Abbildungen jeder Zelle, wurden verschiedene 
zelluläre Kompartimente, wie Nukleus, Lipidtropfen und Zytoplasma, differenziert und 
separat ausgewertet. Wurden ausschließlich spektrale Informationen von 
zytoplasmatischen Lipiden verwendet, verbesserte sich die Vorhersagegenauigkeit des 
Klassifikationsmodells auf 96 % im Vergleich zu Nuklei mit 91 %, Zytoplasma mit 87 % 
und der gesamten Zellinformation mit 93 %. Zusätzlich wurden die metabolischen 
Veränderungen der HCC-Zellen anhand von Raman-Spektren während verschiedener 
Proliferationsphasen erforscht. Gezeigt wurden erhöhte Expressionswerte von 
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ungesättigten Fettsäuren während der Proliferation, im Vergleich zur Apoptose. 
Abweichungen in den Raman-Spektren erlaubten uns das Proliferationsverhalten der 
Zellen mit einer Genauigkeit von 99 % zu klassifizieren und vorherzusagen. 
Um die diagnostischen Kapazitäten der Raman-Spektroskopie auf der Gewebe-Ebene 
zu untersuchen, wurden vordefinierte maligne und nicht maligne Bereiche der 
Patientenproben mit dem HCC analysiert. Wir waren imstande, Lipide, Proteine, 
Kollagen und Cholesterinester als separate Komponenten innerhalb der Raman-
Abbildungen zu detektieren und deren Verteilung in verschiedenen hepatischen 
Läsionen auszuwerten. Ein Random Forest Klassifikationsmodel erlaubte uns, die HCC-
Geweberegionen mit einer Sensitivität von 76 % und einer Spezifizität von 93 % 
vorherzusagen. Die wichtigsten und für das Model bedeutendsten Raman-Banden 
wurden als Fettsäure-Banden, insbesondere Palmitinsäure, identifiziert. Von diesen ist 
bekannt, dass sie eine bedeutende Rolle bei der Entstehung von HCC haben. Des 
Weiteren wurde der entwickelte Klassifizierer genutzt, um Tumorgrenzen zwischen 
HCC-Gewebe und der umgebenden Fibrose vorauszusagen. Demzufolge weist die 
Raman-Spektroskopie ein großes Potential zur operativen Feststellung von 
Grenzzuständen auf, insbesondere von Tumorgrenzen. 
Als zweite diagnostische Analysetechnik wurde die MALDI IMS zur Lokalisation 
verschiedener Proteine innerhalb maligner und nicht maligner Geweberegionen 
angewandt. In der HCC-Geweberegion wurden im Vergleich zur Region ohne 
Lebertumor vier Proteine (6274, 6647, 6222 und 6853 m/z) mit signifikant erhöhtem 
Expressionsprofil identifiziert. Das auf die drei bedeutendsten Proteine entwickelte 
Klassifikationsmodell, erlaubte die Vorhersage von HCC mit einer Sensitivität und 
Spezifizität von 90 %. 
Zusammenfassend konnte gezeigt werden, dass die erhaltenen Ergebnisse der 
bildgebenden Raman und MALDI IMS Technik erfolgreich zur Detektion und 
Lokalisation einer Vielzahl von Molekülen innerhalb einer Probe führten. Wir belegten, 
dass die Raman-Spektroskopie markierungsfrei molekulare Veränderungen in der 
Leber-Karzinogenese auf zellulärer und Gewebe-Ebene effektiv einordnen und 
voraussagen konnte. Zusätzlich lieferte die Anwendung von MALDI IMS spezifische 





1.1 Liver cancer and hepatocellular carcinoma 
1.1.1 Definition of liver cancer 
The earliest description of the primary liver cancer as an independent disease was given 
by C.A. Rokitansky in 1849 (Kuntz and Kuntz, 2008). Thereafter, the existence of both 
primary and secondary (metastatic) liver tumors was accepted. Today primary liver 
carcinoma is the sixth most common cancer type with more than 749 000 new cases per 
year and is the third leading causes of cancer mortality worldwide (EORTC, 2012; IARC 
and WHO, 2014). Hepatocellular carcinoma (HCC) and Cholangiocellular carcinoma 
(CCA) are the most common types of primary liver cancer with an occurrence rate of 
90 % and 10 %, respectively (EASL and EORTC, 2012; Kuntz and Kuntz, 2008). 
1.1.2 Hepatocellular carcinoma 
Epidemiology and risk factors 
HCC is a cancer that originates in liver cells (hepatocytes) and accounts for more than 
692 000 cases per year (Behne and Copur, 2012). Because of the poor prognosis, the 
number of HCC related deaths is almost the same: 589 000 (Parkin et al., 2005). This 
type of liver cancer affects persons of all age groups, but is more common in elderly 
(older than 70 years), and there is a higher incidence among men than women (2.4 : 1) 
(EASL and EORTC, 2012; Kuntz and Kuntz, 2008). The majority of cases are 
associated with liver cirrhosis, which makes early diagnosis of HCC complicated. 
The occurrence rate of this disease varies with geographical location and correlates with 
distribution of Hepatitis B virus (HBV) or Hepatitis C virus (HCV) infections (Kuntz and 
Kuntz, 2008). The high incidence of HCC (85 % of all cases) observed in sub-Saharan 
Africa, East Asia and Melanesia, whereas the incidence is low in developed areas 
except for Southern Europe (10.5 per 100 000 inhabitants) (EASL and EORTC, 2012). 
The main risk factors for development of HCC in Asia and Africa are HBV (70 %), HCV 
(20 %) and aflatoxins (10 %); and in Europe and the USA: HCV (ca. 60 %), alcohol 
(20 %) and HVB (ca. 15 %) (EASL and EORTC, 2012; Kuntz and Kuntz, 2008). 
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Additional factors influencing development of HCC can be seen in Figure 1 (Bergk and 
Schott, 2011). 
 
Figure 1. Risk factors for HCC development. The size of the circles correlated with the 
significance for each risk factor. Adapted from Bergk and Schott (Bergk and Schott, 2011). 
Symptoms and diagnostic 
Often, patients with suspected HCC admitted with symptoms of underlying liver 
diseases (Sugano et al., 1994). In about 70-80 % of HCC cases the disease is 
coexisting with liver cirrhosis, that often results in complications such as 
encephalopathy, ascites, jaundice or bleeding (EASL and EORTC, 2012; Sugano et al., 
1994; Zhu et al., 2013). The main symptoms of HCC are abdominal pain, bloating, 
flatulence, loss of appetite, nausea, weight loss, fatigue, weakness and stool irregulation 
(Kuntz and Kuntz, 2008). 
Until 2000 the diagnostics of HCC was based on biopsy (EASL and EORTC, 2012). Due 
to the risk of complications and the complexity to differentiate between early HCCs and 
high grade dysplastic nodules, the non-invasive criteria was developed in 2001 by 
European Association for the Study of the Liver (EASL). This new criteria is based on a 
combination of imaging (4-phase computed tomography (CT) and dynamic contrast 
enhanced magnetic resonance imaging (MRI)) and laboratory findings (Bruix et al., 
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2001; EASL and EORTC, 2012). In 2005, additions concerning a new HCC radiological 
hallmark for diagnosis of HCC were included by EASL and the American Association for 
the Study of Liver Diseases (AASLD) (Bruix et al., 2001). At present the guidelines from 
AASLD and EASL require for both types of nodules (of 1-2 cm and above 2 cm) 
presence of HCC radiological hallmarks in the imaging techniques CT or MRI (EASL 
and EORTC, 2012). Nevertheless, in case of unclear findings the implementation of 
second medical imaging technique is necessary. 
Such an imaging technique as contrast enhanced ultrasonography is not recommended 
for diagnostic purposes due to lack of specificity for HCC (Halperin et al., 2013). 
Because of often inadequate sampling, liver biopsy, as another diagnostic method, also 
provide a high false negative rate (up to 30%) in diagnostics of HCC (Forner et al., 
2008). Moreover, pathological diagnostics of liver biopsy can often be challenging even 
for an expert in pathology, especially in case when the nodules ranges from 1 to 2 cm 
(Roskams and Kojiro, 2010). Nevertheless, liver biopsy sampling is recommended when 
the diagnostics of HCC cannot be made based on non-invasive criteria because of 
abnormalities in radiological examinations (EASL and EORTC, 2012). Thus, biomarkers 
can improve the examination of the tissue specimens by immunohistochemistry. The 
most promising tissue markers for HCC are glypican 3 (GPC3), heat shock protein 70 
(HSP-70), glutamine synthetase (GS) and/or expression of GPC3, lymphatic vessel 
endothelial hyaluronan receptor and surviving genes (EASL and EORTC, 2012). 
However, even complex staining of GPC3 in combination with HSP-70 and GS can 
provide sensitivity only of 72 % and specificity of 100 % for HCC diagnosis. 
Therapy and prognosis 
Various treatment options can be offered to the patients diagnosed with HCC, including 
liver resection, transplantation, ethanol injection, radiofrequency ablation, transarterial 
embolization and etc. (Table 1) (EASL and EORTC, 2012). The choice of therapy 
depends on the stage, size and number of nodules, as well as on the increased portal 
pressure and elevated bilirubin level, existence of tumor capsule, extrahepatic 




Table 1. Algorithm for staging and treating patients diagnosed with HCC. Adapted from 
Roskams and Kojiro (Roskams and Kojiro, 2010). 
Resection 
 Very early stage, single nodule < 2 cm, 
carcinoma in situ 
 Early stage, single nodule <5 cm, no 
increased portal pressure or elevated 
bilirubin levels 
5-year survival 
40-70 % Liver transplantation 
(CLT or LDLT) 
 Early stage, single nodule <5 cm, 
increased portal pressure and elevated 
bilirubin levels, no associated diseases  
 Early stage, 3 nodules ≤ 3 cm, no 
associated diseases 
PEI or RFA  Early stage, 3 nodules ≤ 3 cm, 
associated diseases 
TAE or TACE  Intermediate stage 
Median survival 
11-20 months 
Kinase inhibitor drugs 
(i.e Sorafenib and 
Doxorubicin) 
 Advanced stage 
Supportive care  Terminal stage 
Survival 
< 3 months 
CLT - cadaveric liver transplantation, LDLT - live donor liver transplantation, PEI - percutaneous ethanol 
injection, RFA - radiofrequency ablation, TAE - transarterial embolization, TACE - transarterial 
chemoembolization. 
Early diagnostics of HCC, when the tumor is around 2 cm in size, allow offering all 
treatment options to the patient. However HCC is often diagnosed at the late stage 
when the disease is in an untreatable condition (Manghisi et al., 1998). Then estimated 
survival of the patient is from 6 to 20 months. Thus, the surveillance strategies and early 
diagnosis of the liver tumor are crucial for potential treatment. 
The median survival in patients with HCC received transarterial chemoembolisation 
(TACE) is around 16 months, for the patients treated with percutaneous ethanol 
injections (PEI) is around 11 months and for the patients receiving TACE followed by 
PEI is around 24 month (Greten et al., 2005). Therefore, the only therapies promising 
good prospects of a cure are liver resection and transplantation, which provides a 5-year 
survival rate of 60-80 % (Llovet et al., 2005; Mazzaferro et al., 1996). While the liver is 
 
 11 
one of two organs in the human body, next to the skin, capable of regeneration, the first-
line treatment for the patients with small single tumor and sufficient liver function is 
tumor resection. This type of treatment provides a surgical removal of the tumor and 
surrounding tissue and preserves a part of the liver sufficient for body function. That 
procedure can be high mortal for cirrhotic patients. In that case more than 40 % of the 
liver needs to be remaining and for non-cirrhotic patients 25 % of liver remnant is 
enough. Surgical resection offers the best prognosis for long-term survival, but is 
recommended only to 40 % of the patients in Asia and to 5 % in the West (Belghiti et al., 
2000; Lang et al., 2005). In cases where the patient is not suitable for resection, liver 
transplantation should be offered as next treatment option in accordance with the Milan 
criteria, that were developed for selecting patients for liver transplantation (Mazzaferro et 
al., 1996). Liver transplantation is the surgical replacement of a diseased liver with a 
healthy donor liver (orthotopic transplantation) or a part of the liver (living donor liver 
transplantation) (EASL and EORTC, 2012). According to EASL clinical practice 
guidelines there is a 5-year survival rate of 65-78 % of the patients and 10-year survival 




1.2 Raman Imaging Spectroscopy 
1.2.1 Theoretical basis of Raman spectroscopy 
During a trip from India to England in 1921 the Indian physicist C.V. Raman performed 
on-board experiments that showed that the color of the sea was a result of direct 
scattering of light and independent from reflection or absorption of light from the sky 
(Ellis et al., 2013). Later this work was submitted to Nature with the title “The color of the 
sea” and refuted the theory suggested by Lord Rayleight that the sea color was just a 
reflection of the color of the sky. After this investigation, C.V. Raman and collaborators 
focused on this new research field in physics; scattering of the light in liquids and solids. 
Thereafter C.V. Raman discovered an inelastic scattering effect in 1928 named after him 
and got the Nobel prize for Physics in 1930. Despite the Raman effect was described 
theoretically by Adolf Smekal already in 1923, it was also observed by C.V. Raman and 
K.S. Krishnan in liquids and by G. Landsberg and L.I. Mandelstam in crystals in 1928 
(Landsberg and Mandelstam, 1928; Raman and Krishnan, 1928; Smekal, 1923). 
Enter into details, the scattering or absorption of the light happens when a photon of 
light impact on a particle (a molecule or an atom) in the ground state (Dieing et al., 
2011). If there is no energy transfer between the photon and the particle, e.g. due to the 
smaller molecule size compared to the radiation wavelength, the effect is called elastic 
or Rayleigh scattering. This scattering will not change the material, hence the 
frequencies of the incident and scattered radiation will remain the same. Nevertheless, 
by interacting with the molecule, individual atoms or groups of atoms of which can 
oscillate relative to the other part of the molecule, the emitted radiation will possess 
long-wave or short-wave frequency shifts with respect to the initial excitation radiation at 
a frequency ω. Thus, scattering with the shifted to lower frequencies (ω-Ω) corresponds 
to the case of a Stokes Raman scattering, while shifted to higher frequencies (ω+Ω) 
gives an anti-Stokes Raman scattering, where Ω is vibrational frequency of molecule. 
These three effects can be displayed via Jablonski diagram (see Figure 2).  
Raman spectroscopy is an optical approach utilizing Raman scattering for the analysis 
of substances. This technique provides information on molecular level by investigating 




Figure 2. Schematic representation of the Jablonski diagram. Adapted from Pavlina 
(User:Pavlina2.0, 2009)). 
Popp, 2006). The spectra of Raman scattered light are unique fingerprints with specific 
spectral bands providing direct information about functional groups, bonding types and 
molecular conformation of solid, liquid or gaseous materials. A meanwhile relatively 
straightforward technical setup and great molecular sensitivity has led to the fact that 
Raman spectroscopy has become a powerful tool not only for chemical analysis but also 
in other research fields. The implementation of Raman spectroscopy in the Mars mission 
of European Space Agency and National Aeronautics and Space Administration is a 
good example for its wide application. And what is of high interest, Raman spectroscopy 
has recently made significant progress in the field of biomedicine (Movasaghi et al., 
2007). 
1.2.2 Biomedical applications of Raman spectroscopy  
As it was outlined above, Raman spectroscopy is a non-destructive and label-free 
technique for in situ investigation of molecular information in a sample. Beginning with 




Figure 3. Schematic layout of a Raman microscope. Adapted from Dieing et al. (Dieing et al., 
2011).  
science revealing studies of cell identification, as well as molecular signatures of 
diseases and individual bacteria (Bielecki et al., 2012; Kloss et al., 2013; Neugebauer et 
al., 2010a). Furthermore, recent developments in optics allow a combination of Raman 
spectroscopy and high resolution confocal microscopy that provides a new non-invasive 
method to image a sample. Figure 3 shows a typical Raman microscope system 
including a spectrometer with a charge-coupled device (CCD) detector, an excitation 
laser and a microscope body. The possibility to image a sample point by point is 
provided by a piezo-driven stage. The optimization of the throughput of the Raman 
microscope is crucial due to the weak Raman signal (approximately 1 of 10 million of 
emitted photons) (Dieing et al., 2011). 
Because of the submicron resolution (<1 µm) Raman spectroscopy in combination with 
confocal microscopy allows imaging of cellular organelles, including nucleus, lipid 
droplets, nucleoli, mitochondria and cytoplasm without use of fluorescent dyes. Diversity 
in the cell morphology and organelle composition allows identification of different cell 
types by Raman imaging spectroscopy (Bocklitz et al., 2009; Chan and Lieu, 2009; 
Chan et al., 2009; Ghita et al., 2012; Harris et al., 2009; Harz et al., 2008; Hawi et al., 
1996; Hedegaard et al., 2010; Jess et al., 2007; Lerou and Daley, 2005; McNeish, 2004; 
Neugebauer et al., 2010b; Oshima et al., 2010; Schulze et al., 2013; Tan et al., 2012; Yu 
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et al., 2006). Time dependent changes of the organelles in size, amount, shape or 
composition as a response to stress factors can be successfully used as differentiating 
criteria (Guarracino et al., 2011; Kourtis and Tavernarakis, 2009; Krafft et al., 2006; 
Kroemer et al., 2010; Short et al., 2005; Verrier et al., 2004). Raman bands associated 
with the nucleus allow investigating changes during cell cycle, proliferation stages and 
apoptosis of the cells (Guarracino et al., 2011; Huser et al., 2009; Krafft et al., 2006; 
Matthäus et al., 2006; Short et al., 2005; Verrier et al., 2004). In addition, treatment 
effectiveness and drug delivery which are of high interest for pharmaceutical science 
have been monitored successfully by Raman spectroscopy as a label-free and non-
invasive technique in recent years (Wilson and Jordan, 1995; Zoladek et al., 2011). 
Apart from cell studies, the use of Raman spectroscopy in tissue diagnostics has a big 
potential based on developments of fiber optic probes that will allow the use of this 
method during endoscopy in clinical routine in future. The submicron resolution of the 
Raman imaging system allows detection of different biochemical compounds in tissue 
sections. The correlation of the obtained Raman spectral information with tissue 
morphology after subsequent histological staining, which is currently a gold standard 
method for cancer diagnostics in histopathology, can provide additional diagnostic value. 
Nowadays, Raman imaging has already been successfully applied as an ex vivo 
diagnostic method to investigate colon, cervical, brain, oral and stomach malignant 
tissues (Beljebbar et al., 2009; Bergholt et al., 2010; Bergner et al., 2012; Guze et al., 
2014; Kamemoto et al., 2010; Lloyd et al., 2012; Mavarani et al., 2013; Patel et al., 
2011). A special attention is paid on the application of fiber optic probes for in vivo 
diagnostics. The use of Raman probes in bronchoscopy, endoscopy of the upper 
gastrointestinal tract and miniaturized Raman endoscope in mice have demonstrated 
the proof of principle for in vivo studies (Bergholt et al., 2010; Short et al., 2008; 
Taketani et al., 2013). 
Based on data from The World Health Organization 216 infectious diseases caused by 
viruses, bacteria and macro-parasites leads to 25 % of all deaths worldwide (IARC and 
WHO, 2014). Due to the submicron resolution Raman spectroscopy is also suitable for 
identification of pathogens (Kloss et al., 2013; Schröder et al., 2013). Moreover, Raman 
spectroscopic investigations of malaria, meningitis, chlamydia infections and 
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sepsis show its applicability in microbiology (Asghari-Khiavi et al., 2011; Harz et al., 
2008; Kang et al., 2011; Neugebauer et al., 2014; Puskar et al., 2007; Szaszák et al., 
2013). 
During the last decade, Raman spectroscopic imaging found a variety of applications in 
biomedicine (as described in chapter 4.1) that proves the possibility of its future use as a 
diagnostic tool in the clinic. Nevertheless, there are both advantages and disadvantages 
of this method that can be seen in Table 2. 
Table 2. Advantages and disadvantages of using Raman spectroscopy for biomedical 
applications  
       Advantages       Disadvantages 
+   Non-destructive 
+   Label-free 
+   High resolution 
+   Composite “fingerprint” spectral 
information 
+   Simple sample preparation and 
small sample amount 
+   Weak water scattering 









-   Weak Raman signal 
-   Autofluorescence 
-   Lack of sensitivity for low concentrations 
-   Chemometric data analysis is necessary 
-   Long measurement time 
-   Individual molecular component 







1.3 MALDI imaging mass spectrometry 
Matrix-assisted laser desorption/ionization imaging mass spectrometry (MALDI IMS) is 
the modern technique that combine highly selective and sensitive mass spectrometry 
with spatial analysis, allowing visualization of a large amount of analytes (proteins, 
peptides, lipids and other small molecules) within a sample (Dudley, 2014). By been 
originally focused on the analysis of intact proteins and peptides, MALDI IMS has found 
nowadays various applications in the analysis of lipids, genotypes and micro-organisms 
as well as discovery of biomarker and metabolomics (Wiley and McLaren, 1955). 
After the ionization process was described in 1980s, the development of first MALDI 
mass spectrometers started by two independent groups and was completed in 1990s 
(Dudley, 2014). MALDI IMS involves mixing of the molecules of interest from the sample 
with the matrix solution (usually organic acids) and co-crystallization of them together 
(Aichler and Walch, 2015). By applying pulsed UV-laser to the sample inside of MALDI 
ion source, matrix will absorb the energy and molecule will be desorbed and ionized into 
the gas phase (Figure 4). Depending on the choice of matrix type and technology, 
different analyte classes such as peptides, proteins, lipids, oligonucleotides and drugs 
can be investigated (Norris and Caprioli, 2013). The ion sources in MALDI IMS are 
combined with time of flight (TOF) chambers, where ions getting separated (Yalcin and 
de la Monte, 2015). Produced equal charged ions will have the same kinetic energy, but 
variation in ion velocities based on different masses. Therefore, by separating ions in 
high vacuum of TOF analyzer, smaller particles will move faster and reach the detector 
earlier than heavy particles, what will be determined in mass-to-charge ratio (m/z) (Wiley 
and McLaren, 1955). As a result the molecular maps with spatial distribution of m/z 
value of interest for each x and y coordinate will be generated. For further analysis 
obtained MALDI image can be compared to a histological stained microscope image 
(like hematoxylin and eosin stain (H&E), immunohistochemistry et al.) and co-registered 
to the mass spectrometric data (Aichler and Walch, 2015; Gessel et al., 2014; Wiley and 
McLaren, 1955). 
Depending on the experimental purposes MALDI IMS analysis can involve a number of 
steps, however the critical step is a complex sample preparation on behalf of 
optimization of sensitivity and spatial resolution. Typically, sample preparation starting  
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Figure 4. Principle of MALDI IMS. Adapted from Marvin et al. (Marvin et al., 2003).  
with mounting thin tissue slice on conductive slide or sample homogenization, followed 
by centrifugation, extraction, washing or fixation steps (Dudley, 2014; Groseclose et al., 
2008; Meding and Walch, 2013). Afterwards coming to the choice of matrix and 
heterogeneity of matrix crystallization and its application on a sample (Norris and 
Caprioli, 2013). Furthermore, two additional steps are necessary to be performed before 
the MALDI IMS measurement will take place (Yalcin and de la Monte, 2015). The first 
step is a calibration of the system to protein or peptide standards for specificity of 
obtained m/z ratio. The second one is to mark the sample with three teaching points for 
future coregistering with histological stained microscope image. The final step, after the 
MALDI IMS measurements were completed, is statistically correct interpretation of 
complex and extensive mass spectrometric data sets. It can be performed by standard 
control software provided by the inventors (e. g. Bruker Daltonik GmbH, Bremen, 
Germany) and by software programs introduced in recent years for processing MALDI 
IMS data (Norris and Caprioli, 2013). 
By been able to detect tissue biomarkers, classify tumors, provide early diagnosis or 
prognosis, elucidate the pathways of pathogenesis and monitor therapy, MALDI IMS 
mass spectrometry has been applied for investigations of various diseases with the 
primary focus on cancer (Rodrigo et al., 2014). Over recent years, MALDI imaging has 
been used for investigation of gastrointestinal cancer, cancer of respiratory system, 
bladder, prostate, breast and ovaries (Alexandrov et al., 2013; Cheng et al., 2012; 
Chuang et al., 2012; Longuespée et al., 2012; Meding et al., 2012; Oezdemir et al., 
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2012; Rauser et al., 2010; Végvári and Döme, 2011). Further applications of MALD IMS 
in the field of gastroenterology and hepathology will be described in Chapter 4.2. 
Furthermore, the advantages and disadvantages of MALDI IMS mass spectrometry for 
biomedical applications are mentioned in the Table 3. 
Table 3. Advantages and disadvantages of using MALDI IMS imaging mass spectrometry 
for biomedical applications  
       Advantages       Disadvantages 
+   Fast 
+   Label-free  
+   Selective analysis of specific 
molecules 
+   Analysis of samples with large size 
+   Suitable for large number of samples 
+   Possibility of direct identification of 
the analyte  









-   Complex and expensive sample                  
preparation  
-   Low reproducibility   
-   Limits in spatial resolution 
-   Long measurement time 
-   Limited detectable mass range 





2. Aim of the work 
The aim of this work was to develop new classification models for identification and 
classification of different types of liver cancer based on novel imaging techniques. 
Therefore, Raman spectroscopic imaging as a non-invasive, non-destructive and label-
free method was used in order to develop classification models for liver cancer 
identification and prediction on both cellular and tissue levels. Furthermore, MALDI IMS 
mass spectrometry as a second method for analysis of specific biomarkers in malignant 
and non-malignant tissue regions in liver was applied. 
 
The following aims were central in our research investigations: 
1. To characterize and classify different types of liver cancer cells by Raman 
spectroscopic imaging. 
2. To investigate metabolic changes during proliferation and apoptosis in HCC cells 
based on Raman spectra. 
3. To test the reproducibility of Raman spectroscopic imaging as a diagnostic 
method. 
4. To investigate molecular information of different hepatic lesions by Raman 
imaging aiming to classify and predict HCC. 
5. To develop an algorithm for comparative analysis of main macromolecular 
components in liver cancer tissue sections. 
6. To detect the borders of liver tumor in the hepatic specimens for surgical margin 
status application. 
7. To apply MALDI IMS for identification of specific biomarkers associated with 
HCC. 
8. To develop new classification model for diagnostics of HCC based on protein 
signatures detected by MALDI IMS.  
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3. Peer-reviewed publications 
Publication 1: 
Discrimination and Classification of Liver Cancer Cells and 
Proliferation States by Raman Spectroscopic Imaging 
 
 
Tatiana Tolstik, Claudio Marquardt, Christian Matthäus, Norbert Bergner, 
Christiane Bielecki, Christoph Krafft, Andreas Stallmach, Jürgen Popp 
 
Published in:  
Analyst, 2014; 139(22):6036-43. 
IF (2014): 4.107. 
 
In this study the investigation of different liver cancer cell lines, i.e. HepG2 - well 
differentiated hepatocellular carcinoma cell line and SK-Hep1 - liver cancer cell line from 
a patient with adenocarcinoma, applying Raman imaging was performed. The 
identification and classification of different types of liver cancer cells (n = 100) by 
applying a support vector machine (SVM) classification algorithm allow to predict cell 
types with accuracy of 93 %. It was found out that the main difference between both cell 
lines can be attributed to Raman signatures of unsaturated fatty acids. Different cellular 
compartments could be distinguished by hierarchical cluster analysis (HCA) and 
analyzed separately. Therefore, separate use of spectra of the cytoplasmic lipids allows 
us to improve the classification to 96 %, compared to nucleus (accuracy of 91 %), 
cytoplasm (accuracy of 87 %) or the complete spectroscopic information of investigated 
cells (accuracy of 93 %). Furthermore, high expression of unsaturated fatty acids was 
detected in the proliferation phase of HCC cells which allowed us to classify and predict 





















Classification and Prediction of HCC Tissues by Raman Imaging with 
Identification of Fatty Acids as Potential Lipid Biomarkers
 
 
Tatiana Tolstik, Claudio Marquardt, Claudia Beleites, Christian Matthäus, 
Christiane Bielecki, Martin Bürger, Christoph Krafft, Olaf Dirsch, Utz Settmacher, 
Jürgen Popp, Andreas Stallmach 
 
Published in:  
Journal of Cancer Research and Clinical Oncology, 2015 Mar; 141(3):407-18. 
IF (2014): 3.081. 
 
Based on our previous study, Raman imaging was applied for tissue investigations in 
order to differentiate, classify and predict malignant and non-malignant regions of the 
liver. Thus, different components in a tissue such as lipids, proteins, collagen and 
cholesterol ester by N-finder algorithm (N-FINDER) were detected by Raman imaging. 
After analyzing their distribution in the samples the detection of the main components of 
HCC and fibrotic tissue regions was possible. The predefined malignant and non-
malignant tissue regions were used for a comparative analysis and calculated Random 
forest (RF) classifier with a sensitivity of 76 % and specificity of 93 % to predict HCC. 
The most significant spectral differences were identified as fatty acids. Furthermore, 
three of the most significant bands were attributed to palmitic acid. Subsequently, we 
applied the developed classification algorithm to tumor margins in order to verify the 
predictive performance of the classifier. Predicted borders of the tumor were correlated 
with H&E stained tissue regions and showed high potential of Raman spectroscopic 









































MALDI imaging-based classification of hepatocellular carcinoma and 
non-malignant lesions in fibrotic liver tissue 
 
 
Claudio Marquardt, Tatiana Tolstik, Christiane Bielecki, Roland Kaufmann, 
Anna C Crecelius, Ulrich S Schubert, Utz Settmacher, Andreas Stallmach, Olaf Dirsch 
 
Published in:  
Zeitschrift für Gastroenterologie, 2015 Jan; 53(1):33-39. 
IF (2014): 1.052. 
 
As the second method for molecular imaging of the biological specimens MALDI IMS for 
proteomic analysis of liver cancer was applied. Therefore, the cryosections with 
malignant HCC regions (n = 25) and non-malignant fibrotic (n = 11) and regenerative 
nodules (n=8) regions in hepatic specimens were measured. Overall 116 protein peaks 
were detected in measured liver samples. After staining of the investigated tissue 
sections with H&E we were able to correlate mass spectral information with histology. 
Based on that, an overexpression of previously unknown proteomic patterns at 6222, 
6274, 6647 and 6853 m/z was detected in HCC regions. Furthermore, based on most 
significant three protein peaks (6274, 6647 and 6222 m/z) a classification model was 
developed and resulted in 90 % of sensitivity, specificity and accuracy for prediction of 
previously unknown HCC regions in cirrhotic liver tissue. This work showed high 
potential of MALDI IMS for identification of novel protein biomarkers for HCC diagnostics 






























Patients with developed HCC mostly have no symptoms besides those related to their 
underlying chronic liver disease and cirrhosis (Sugano et al., 1994). In general, HCC 
mostly discovered while routine screening or because of dominant symptoms associated 
with tumor size or location. HCC tumors are presented as a single lesion or as a diffuse 
mass, what can be difficult to distinguish from the surrounding cirrhotic tissue and 
regenerative nodules by available imaging studies (Kuntz and Kuntz, 2008). Nowadays, 
only aggressive measures such as surgical resection, ablative therapy or liver 
transplantation provide promising survival prognosis for the patients with HCC. Against 
that background, novel molecular imaging techniques should be considered in order to 
diagnose and predict the extremely malignant and rapidly progressing liver tumor at the 
early stage. 
4.1 Application of Raman spectroscopy for liver cancer 
investigations 
Different optical techniques such as Raman, Surface-enhanced Raman (SERS), 
Coherent anti-Stokes Raman spectroscopy (CARS) and Laser tweezers Raman (LTRS) 
spectroscopies as well as Raman spectroscopy in combination with Laser-induced 
fluorescence (LIF) have been applied for liver cancer diagnostics (Guo et al., 2009; Hawi 
et al., 1996; Li et al., 2004; Santiago-Cordoba et al., 2011; Taleb et al., 2013; Wang et 
al., 2009; Wu et al., 2009; Xiong et al., 2012). 
In 1996 Hawi et al. have published the first investigations of malignant and normal 
hepatocytes by single point Raman spectroscopy in culture and in tissue samples (Hawi 
et al., 1996). In this study they were able to detect spectral differences in single Raman 
bands and showed the future potential of this method. Later, similar work was performed 
by Guo et al. where they applied a linear discriminant analysis for identification of 
malignant hepatocytes (Guo et al., 2009). First work with serum samples from patients 
with HCC and a control group were investigated by Taleb et al. applying micro-Raman 
spectroscopy in 2013. Here principal component analysis (PCA) allowed separating 
patients into two groups (with and without HCC). In contrast, SVM classification model 
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using leave-one-out cross validation algorithm provided an accuracy from 84.5 to 90.2 % 
for dried serum drops and from 86 to 91.5 % for freeze-dried serum drops (Taleb et al., 
2013). Another work with serum samples was published by Santiago-Cordoba et al. 
(Santiago-Cordoba et al., 2011). In that work SERS was applied for serum analysis of 
the HCC patients with HBV or HCV infections and provide fast (< 10 s) and reproducible 
(<5 %variation) detection.  In addition, Raman spectra of oxyhemoglobin of liver cancer 
patients (n = 30) and healthy persons (n = 30) were measured by SERS that allowed to 
discriminate between two groups with an accuracy of 93.3 % (Xiong et al., 2012). 
Another type of Raman spectroscopy, CARS, was used for the quantitative assessment 
of fat in intact liver tissue reported by Wu et al. (Wu et al., 2009). Along with it a LTRS 
has been applied for identification of liver cancer cells, para-cancer cells and normal 
hepatocytes (Wang et al., 2009). In this study, intensity differences at 1070, 1266, 
1445 cm-1 were detected in the Raman spectra of different cell types. The article 
published in 2004 by Li et al. showed that patients without liver cancer had three sharp 
Raman bands in their serum samples in contrast to patients with liver cancer. Also the 
pick shift in fluorescence, that were observed for healthy patients compared to one with 
liver fibrosis and cirrhosis, was detected by LIF (Li et al., 2004). 
Despite of all above mentioned methods, our research group has applied Raman 
spectroscopic imaging as an innovative technology for diagnostics of liver cancer for the 
first time. Raman imaging combines the spatial resolution of microscopic imaging with 
highly specific spectroscopic information of classical Raman spectroscopy. In order to 
achieve this goal, different studies to investigate liver cancer on the cellular and tissue 
levels for patients with HCC were planned and achieved (see Chapter Aim of the work). 
Identification and classification of HCC cells by Raman imaging 
spectroscopy 
The aim of this study was to differentiate and classify by Raman imaging spectroscopy a 
hepatocellular carcinoma HepG2 cell line (the most common primary liver cancer) and 
an adenocarcinoma SK-Hep1 cell line (found in an ascites fluid of the patient with liver 
cancer). In contrast to previous research studies, the identification of the different cell 
types was based on spectral information collected from the whole cell with the step size 
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of 1 µm rather than from single point measurements, published by Goa et al. and Hawi 
et al. (Guo et al., 2009; Hawi et al., 1996). This allowed us to gain more specific 
chemical information and identify subcellular components, including nucleic acids, 
proteins, carbohydrates and cytoplasmic lipids within each measured cell. Thus, 
differences in Raman spectral information for different cellular organelles were detected. 
The difference spectra represent significant spectral changes in the Raman bands from 
2900 to 2850 and at 1655, 1440, 1304, 1266 and 1060 cm-1. Further analysis of this 
data with HCA has divided HepG2 and SK-Hep1 cells into two major clusters without 
any misclassification. The application of SVM classification algorithm to the data set 
allowed us to identify previously unknown cells with an accuracy of 93 %. Precise 
analysis of Raman spectra showed that two cell lines differed mainly in specific spectral 
patterns of unsaturated fatty acids. Therefore, the use of SVM algorithms for each 
cellular compartment separately improved the accuracy of the classification model up to 
96 % for cytoplasmic lipids compare to nucleus, cytoplasm or complete cell information 
with accuracies of 91 %, 87 % and 93 %, respectively. 
As was found in our investigations, the lipid synthesis plays an important role in 
carcinogenesis in the liver. In 2005, high expression of lipogenic enzymes by mRNA in 
HCC liver tissue was described by Yahagi et al. (Yahagi et al., 2005). Another study 
showed upregulation of lipogenic enzymes, which are involved in the fatty acid synthesis 
and cholesterol biosynthesis as well as their upstream inductors in non-tumorous liver 
tissue in contrast to HCC. Furthermore, this study discovered clinical aggressiveness 
based on a correlation of higher expression of enzymes with an activation of a lipogenic 
signalling pathway (Calvisi et al., 2011). 
The second part of this study was based on analysis of the proliferation behavior of HCC 
cells by Raman imaging spectroscopy. The main difference between actively dividing 
cells and cells in apoptosis was found to be in the higher amount of fatty acids in 
dividing cells. Similar results were achieved by Gao et al. based on single point Raman 
spectroscopy. He showed that the inhibition of the fatty acid synthesis causes a cell 
cycle arrest of HepG2 cells (Gao et al., 2006). The state of cell proliferation can be 
predicted by Raman spectral bands for HepG2 cells in the exponential and plateau 
phase with sensitivity of 100 % and specificity of 98 %. 
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Based on the results of this study, in our forthcoming investigations we would like to 
focus on the Raman based analysis of brush cytology acquired during endoscopic 
retrograde cholangiopancreatography for diagnostics of CCA. 
Identification and classification of HCC tissue by Raman imaging 
spectroscopy 
The meaning of diagnostics in the clinical routine nowadays includes laboratory 
analyses, imaging studies (CT and MRI) as well as cytological and histological 
investigations of tissue samples. The identification of measurable indicators 
(biomarkers) in biological specimens is crucial for the development of an effective 
diagnostic method to identify the underlying disease. Raman spectroscopy in 
combination with confocal microscopy allows the detection of various markers in the 
sample. This “fingerprint” information can be used for objective tumor differentiation and 
classification of different types of tissue. 
Following the previous study about classification of different types of liver cancer cells 
and their proliferation states, the aim of this project was to investigate different regions 
of human HCC tissue by Raman imaging spectroscopy. Therefore we measured 
predefined malignant (HCC, n = 12) and non-malignant (fibrosis, n = 17) tissue regions 
for comparative analysis. Despite high similarities of the Raman spectral signature of 
biomolecules, the chemometric data analysis can be applied in order to identify, classify 
and predict HCC. Precise analysis of different spectra allows us to detect changes in 
lipids together with proteins in HCC tissues and collagen together with proteins in fibrotic 
regions. Applying the N-FINDER algorithm we obtained four independent spectral 
endmembers for proteins, triglycerides, collagen and cholesterol esters. Differences in 
the distribution of the molecules in the Raman maps showed high heterogeneity of HCC 
samples with a prevailing amount of lipids or proteins depending on the patient. 
Because of the complexity of the data set, a nonlinear RF was chosen to predict HCC. A 
101x iterated sevenfold cross-validated model resulted in sensitivity of 76 % and 
specificity of 93 % (accuracy of 86 %). Therefore, we can conclude that based on 
Raman imaging spectroscopy combined with RF classification model 94 patients with 
HCC from 100 will be correctly identified as having cancer. And 77 healthy patients from 
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100 will be identified as healthy. Nevertheless, 23 patients with HCC will be incorrectly 
identified as healthy and 6 healthy patients will be misclassified as having cancer. The 
variable importance plot demonstrated most significant bands for classification at the 
wavenumbers 2856, 1298, 937, 920, 1439, 1080, 2895, 1023, 1063 and 719 cm-1 
(ranked in order of importance). The correlation of the Raman peaks with reference data 
bases of Raman spectroscopy showed that four out of ten bands can be identified as 
palmitic acid in HCC tissue (Bonifacio and Sergo, 2010; Bonifacio et al., 2010; De 
Gelder et al., 2007; Köhler et al., 2009; Krafft et al., 2005). Furthermore, we applied the 
classifier to Raman imaging maps of tumor margins and the bordering fibrotic tissue to 
confirm the prediction of the developed classifier. Therefore an algorithm that provides 
prediction maps with color-intensity scales depicting the positive diagnose for HCC was 
generated. The predictive performance of the algorithm by its correlation with the 
corresponding tissue architecture on H&E stained regions were verified. 
The results of this study are in a good agreement with our previous article where we 
identified and classified liver cancer cells and proliferation states by Raman imaging. 
The main differences that we found between HCC and adenocarcinoma cells were in 
the high amount of unsaturated fatty acids in HCC cells and especially during 
exponential growth phase. It is known that high lipid biosynthesis plays an important role 
in carcinogenesis of HCC. Overexpression of mRNA for fatty acid synthase, acetyl-CoA 
carboxylase and ATP citrate lyase was described by Yahagi et al. (Yahagi et al., 2005). 
In additional upregulation of lipogenic enzymes, which is involved in the fatty acid 
synthesis and cholesterol biosynthesis, was detected in HCC tissue. Later an activation 
of a lipogenic pathway (AKT-mTORC1-RPS6) was correlated with aggressiveness of 
HCC (Calvisi et al., 2011). Subsequently, work published by Budhu et al. showed 
increased level of palmitic acid in aggressive HCCs, that confirm our results about 
Raman signatures of palmitic acid to predict HCC. 
Different types of lesions and surgical margin status of HCC was predicted by Raman 
imaging spectroscopy with 86 % of accuracy. As a non-destructive and label-free 
imaging technique this method could allow to perform in vivo diagnostics of HCC without 
taking biopsies in the future. Thereby, Raman imaging can provide a fast prediction of 
cancer or other diseases in the clinics. 
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Data analysis of Raman spectroscopic data 
Analysis and interpretation of the spectral information are crucial steps in Raman 
imaging. Detected molecular changes in biological specimens require the application of 
statistical methods (e.g. preprocessing, multivariate imaging, classification) in order to 
extract diagnostic information. After the sample collections and preparation, followed by 
Raman measurements we obtain raw Raman spectra that should be preprocessed by 
cosmic spike removal, quality test, baseline corrections, normalization and spectra 
calibration, if necessary (Bielecki et al., 2012; Kloss et al., 2013; Neugebauer et al., 
2010b). These steps are important for extracting undesirable fluorescence, burning 
artifacts, contaminants and cosmic ray features, as well as for the intensity correlation 
that allows to have comparable data sets with recognizable differences. As the next 
steps the supervised (classification methods) and unsupervised (clustering methods) 
algorithmic approaches can be applied to the data sets. The classification models, like 
SVM or RF, allow to classify and predict unknown sample sets. At the same time the 
cluster analysis, like HCA or N-FINDER, allow combining data sets into the groups 
(clusters or endmembers), which correspond to different cell or tissue types, or even  
 
Figure 5. Schematic representation of processing pathway for Raman spectroscopic 




different chemical components within the data set. This analysis can be performed by 
using programming languages Matlab and R with self-written scripts or available 
toolboxes as well as by applying such softwares like Cytospec or OPUS.  
For all our experiments we used different chemometrical algorithms and developed a 
strategy for processing and interpretation of spectral information collected during Raman 




4.2 Application of MALDI IMS for liver cancer investigations 
During development of cancer, surrounding microenvironment and cells themselves 
synthetize molecules, such as proteins and peptides, in a different way as normal cells. 
These variations in types and concentrations of the molecules can be successfully 
analyzed by spectrometric methods and the patterns can help to identify specific 
biomarkers for clinical approval. MALDI IMS is considered to be a powerful method for 
molecular imaging with the great potential to be used as a diagnostic tool in studies of 
cancer (Norris and Caprioli, 2013). 
Over recent years MALDI IMS has been used in investigation and prediction of different 
cancer types directly in tissue specimens (Chughtai et al., 2012; Dihazi et al., 2013; 
McDonnell et al., 2012). Furthermore, MALDI IMS showed a high potential in the field of 
gastroenterology and hepatology (Balluff et al., 2012). For instance, the study published 
by Cheng et al. showed that human neutrophil peptides 1-3 are synthetized in high 
amount in gastric cancer tissue and can be used for diagnostic and target tumor 
treatment (Cheng et al., 2012). MALDI IMS was applied for investigation of colon cancer 
cells and their metastasing into regional lymph nodes. In that study three novel 
biomarkers responsible for development of metastasis in lymph nodes were discovered 
(Meding et al., 2012). 
The objective of our study was to investigate protein signatures in tissue samples in 
order to identify new specific molecular patterns for diagnostic and prediction of HCC by 
MALDI IMS. For this purpose we analyzed surgically resected liver specimens with 
predefined regions of HCC, regenerative nodules and fibrosis. From 116 detected mass 
values within the tissue samples we were able to identify four peaks (6274, 6647, 6222 
and 6853 m/z) which displayed high expression profile in area of HCC in compare to 
non-malignant areas. In order to identify HCC based on three most significant protein 
peaks (6274, 6647 and 6222 m/z) detected by MALDI IMS, the genetic algorithm-based 
classification model was applied. This analysis allowed us to predict lesions of HCC and 
regenerative nodules with accuracy, sensitivity, and specificity of 90 %. What means, 
only 10 patients from 100 would be misclassified while diagnosis of HCC by MALDI IMS. 
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Recently published work by Le Faouder, showed similar investigations of cirrhotic liver 
tissue specimens with HCC by MALDI IMS (Le Faouder et al., 2011). Proteomic analysis 
was applied to frozen liver tissue (n = 30), where HCC regions were compared with 
cirrhosis in order to characterize new biomarkers. Using a SVM classification model 
based on 13 previously selected protein peaks sensitivity of 83.8 % and specificity of 
86 % was achieved. The most distinguished protein peak was found at 8565 m/z and 
characterized as the monomeric ubiquitin (Ubi). Further investigations by this research 
group demonstrated role of kallikrein-related peptidase 6 that catalyzed the production 
of Ubi in translation from cirrhosis to HCC (Laouirem et al., 2014). Another study 
demonstrated the analysis of tissue proteome of HCC samples allowing to distinguish 
between samples with and without microvascular invasion (Poté et al., 2013). Acquired 
28 peaks were highly expressed in HCC tissue. Furthermore, two of them (3790 and 
5654 m/z) were detected as modified forms of histone H4 and associated with 
microvascular invasion in HCC. Moreover, application of MALDI IMS for analysis of liver 
tissue specimens allow classification of HCC tumors associated with HBV vs. non-tumor 
tissue regions (Han et al., 2011). 
In spite of all previously presented data, in our study no significant correlations with 
results presented by Le Faouder et al. and Han et al. were found. Nevertheless, even if 
no information about overexpression of Ubi (8565 m/z) in HCC was obtain we can take 
into account that two of the proteins peaks, described by Le Faouder et al., highly 
expressed in the HCC tissue were detected in cancer tissue regions measured by us as 
well. This proteomic analysis allows us not only to investigate the protein signatures, but 
as well to obtain their spatial information in HCC, fibrosis and regenerative nodules 
within liver tissue sections. In conclusion, by collecting mass spectrometry data from 
various liver tissues and cells new data base for a fast prediction of cancer or other 
diseases can be developed. Therefore in our study, we developed a new algorithm for 
classification and prediction of HCC vs. non-malignant tissue based on MALDI IMS. In 
our forthcoming studies we would like to focus on analysis of higher number of samples, 




Molecular imaging techniques, such as Raman spectroscopy and MALDI IMS 
spectrometry, allow to investigate various of molecules and their spatial distribution 
within biological specimens. Raman spectroscopy is a biophotonic method for non-
destructive and label-free visualization of vibrational and rotational states of molecules 
at submicron resolution. Raman spectra of biological samples includes the information 
about proteins, nucleic acids, lipids, carbohydrates and provide rapid and specific 
biochemical “fingerprint” for differentiation and classification of malignancies. In contrast, 
MALDI IMS is a powerful technique for analysis and identification of proteins or lipids in 
the biomedical specimens. This method allows to discover specific molecules as 
biomarkers for diagnostic of diseases. Furthermore, by applying the classification 
algorithms to the spectroscopic or spectrometric data, cancer-specific patterns can be 
discovered in order to develop independent prediction models. Therefore, by collecting 
molecular signatures from various liver tissues and cells by Raman and MALDI imaging, 
new data base for the fast prediction of cancer or other diseases can be developed. 
In conclusion, we applied two molecular imaging methods for diagnostic of liver cancer 
on cellular and tissue levels and confirmed that Raman imaging spectroscopy and 
MALDI IMS in combination with multivariate data analysis are able to identify and predict 
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